Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 60.3%

Neg 60.3% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $46 to $40.